- Profound Medical (OTCQX:PRFMF) has received 510(k) clearance from the FDA to market TULSA-PRO for ablation of prostate tissue.
- TULSA-PRO is a transurethral prostate tissue ablation system that combines Magnetic Resonance Imaging with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.
- U.S. commercial launch will start next quarter.